The Long-Acting Injectable Antipsychotics called the LAIs Purchasing Program
A smart solution for independent retail pharmacies:
GeriMed/ComboMed worked with Long-Acting Injectable Antipsychotics manufacturers including Alkermes, Indivior, Johnson & Johnson (Jannsen), Otuska, and Teva to create this exclusive program.
Explore the Benefits and Criteria of the Long-Acting Injectable Antipsychotics LAIs Purchasing Program
Unique advantages
Independent pharmacies that purchase and dispense Long-Acting Injectable Antipsychotics can get most of the benefits typically associated with a “closed-door” pharmacy under your existing retail DEA pharmacy license, and without many of the complex requirements of going “closed-door.” This program assists you in expanding revenue streams and capitalizing on any bottom-line savings through significant discounts and rebates. It also empowers you to have an even broader impact on your community.
Criteria for the LAIs Purchasing Program
The LAIs Purchasing Program applies to patients being treated in or living in where LAI’s are dispensed and administered by a healthcare professional:
- Outpatient Mental Health Centers
- Psychiatric/Mental Health Facilities
- Assisted Living Facilities
- Skilled Nursing Facilities
- Correctional Facilities
- Group Homes
- Intermediate Care Facilities – ICF-IID
- LTC Pharmacy at Home
800-456-4374
502-339-1417